Raven V2
Retirée du marché américain le 14 March 2024 (selon le DSLD)
Rising Labs, food supplement from the US market
Label withdrawn from the US market. Raven V2 (Rising Labs), a food supplement au code-barres 725272730768, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
If this product were sold in France
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Citrus aurantium L.: La quantité ingérée de p-synéphrine doit être inférieure à 20 mg par dose journalière recommandée. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants, aux femmes enceintes ou allaitantes et en cas de traitement anti-hypertenseur. La caféine et les sources de caféine ne sont pas autorisées dans les compléments alimentaires contenant Citrus aurantium L.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Rising Labs
- Barcode
- 725272730768
- Form
- Capsule
- One serving
- 3 vegetarian capsules
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Hydroxypropyl Methylcellulose, Magnesium Stearate, Calcium Silicate
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Ashwagandha (Withania somnifera) root extract (Withania somnifera) | Plant | 300 mg |
| natural Caffeine | Other substance | 275 mg |
| L-Theanine | Amino acid | 200 mg |
| Green Tea (Camellia sinensis) leaf extract (Camellia sinensis) | Plant | 150 mg |
| Green Coffee (Coffea arabica) bean extract | Plant | 150 mg |
| Cayenne Red Pepper (Capsicum annum) fruit powder (Capsicum annuum) | Plant | 100 mg |
| Theobromine | Other substance | 100 mg |
| Citrus aurantium (Citrus aurantium) unripen fruit extract (Citrus aurantium) | Plant | 100 mg |
| Grains of Paradise (Aframomum melegueta) seed extract (Aframomum melegueta) | Plant | 50 mg |
| Methylliberine powder | TBD | 40 mg |
| Gamma-Butyrobetaine Hydrochloride | Other substance | 30 mg |
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Raven
Entered into DSLD on 24 June 2020. Retirée du marché américain le 22 May 2020 (selon le DSLD).- Active ingredient added : Rauwolscine (2 mg)
- Active ingredient removed : Methylliberine powder (40 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ashwagandha (Withania somnifera) root extract
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Cayenne Red Pepper (Capsicum annum) fruit powder
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Rising Labs
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.